Indication intelligence, analysis and sector perception

Lower open expected. RegMed’s pre-open, like pot, we’re in a temporary high

November 3, 2015 6:26am

To think it’s a state we can invest in is not realistic as the high won’t last, without a downer.

Investors will be looking for clues regarding trader’s execution in the days ahead as financial results will hit the nail on its head. Subscription required: http://www.regmedinvestors.com/user/register

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

DOW futures ar DOWN -0.1% and NASDAQ futures are DOWN -0.2%

U.S. stocks set to fall back from the previous day’s solid rally, as stock futures inched lower ahead of prominent earnings and factory-orders data.

European equities fluctuated between positive and negative territory in early morning trade with earnings from UBS and Standard Chartered in focus for investors.

Asian equities advanced, as the morale of investors got a boost from the overnight rally on Wall Street. However, markets in China fell short of broader advances across the region amid jitters surrounding a crackdown on illegal futures trading and ongoing anti-corruption investigations

Data docket: A reading on factory orders for September is due at 10 a.m. ET - expect a drop of 0.9%, following a 1.7% slide in August. Numbers on auto sales for October are expected to come out throughout the day.

The RegMed sector closed POSITIVE on Monday, NEGATIVE on Friday and Thursday, POSITIVE on Wednesday, NEGATIVE on last Tuesday.

Monday closed POSITIVE with 1 decliner, 39 advancers and 3 flats following Friday’s NEGATIVE close with 27 decliners, 14 advancers and 2 flat.

Reiterating, the stem, cell and gene therapy RegMed (SCGT&RM) sector has entered the quarterly sweepstake season. The closer we get to understanding financial results, the easier it will be to process <LPS or loss per share > the more expressive the loss, the leaner the gains are going to be!

Yesterday, I asked where the canaries in the coal mine are, today I question what personifies the early warning system?

Tuesday’s trading indications, stocks to watch:

I have my own thoughts on which companies are overpriced or undervalued – after Monday’s run. I wouldn’t touch any stock in the sector without giving rise to bias!

Be ready for a pricing purge.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.